United States Next Generation Sequencing Market to Surge to US$ 13.75 Billion by 2032 Amid Rapid Technological Advancements and Growing Demand for Personalized Medicine

The United States Next Generation Sequencing (NGS) market is experiencing a transformative boom, forecasted to grow from US$ 3.16 billion in 2023 to US$ 13.75 billion by 2032, at an impressive CAGR of 17.75% from 2024 to 2032, according to Renub Research.

This exceptional growth trajectory is driven by the rapid evolution of genomic technologies, increasing adoption in clinical and agricultural applications, and rising R&D investments in healthcare and biotechnology sectors.

🔬 Technological Innovations Fueling Market Expansion

NGS platforms are revolutionizing genomic sequencing with unparalleled accuracy, scalability, and speed. Technologies such as Sequencing by Synthesis (SBS), nanopore sequencing, and single-molecule real-time sequencing are enabling whole-genome mapping, genetic mutation analysis, and precise disease detection. Illumina, Thermo Fisher Scientific, and QIAGEN continue to lead with cutting-edge innovations, such as Illumina’s MiSeq™ i100 series and Thermo Fisher’s Ion Torrent Genexus Dx system.

🧬 Widening Application Across Healthcare and Research

NGS is becoming indispensable in diagnostics, drug discovery, agricultural research, and personalized medicine. It plays a pivotal role in cancer genomics, prenatal diagnostics, rare disease detection, and pathogen surveillance. The growing prevalence of cancer—projected to hit over 2 million new cases in 2024—is significantly accelerating NGS adoption for oncology diagnostics and treatment personalization.

🏥 NGS Integration in Clinical Practice

U.S. hospitals and clinics are increasingly incorporating NGS into routine workflows for precision diagnostics and targeted therapies. Despite challenges such as high equipment costs and complex reimbursement structures, efforts to expand insurance coverage and reduce sequencing costs are improving accessibility. Initiatives such as the CDC’s $1.7 billion genomic surveillance funding under the American Rescue Plan reflect strong government support.

🧪 Reagents & Consumables Lead Product Demand

The segment for reagents and consumables is witnessing strong demand, fueled by continuous sequencing requirements in research labs and clinical diagnostics. Companies are innovating cost-effective solutions to improve sequencing speed and quality.

💊 Driving Genomic-Driven Drug Discovery

Pharmaceutical companies are harnessing NGS for identifying biomarkers, understanding disease mechanisms, and enabling precision therapeutics. However, data interpretation and privacy concerns remain crucial challenges for wider adoption.

New Publish Reports

🌎 Strategic Collaborations and Market Developments

Recent industry developments include:

• Illumina & Janssen’s collaboration on minimal residual disease assays (2024)
• Pfizer & Thermo Fisher’s partnership to enhance NGS testing access in underserved regions (2023)
• Agilent’s launch of a comprehensive NGS oncology assay (2023)
• Neuron23 & QIAGEN’s joint development of a Parkinson’s diagnostics tool (2023)

📈 Segment Highlights

• By Product: Instruments, Reagents & Consumables, Services
• By Application: Diagnostics, Agriculture & Animal Research, Drug Discovery, Personalized Medicine
• By Technology: SBS, Ion Semiconductor, Nanopore, SMRT
• By End-Users: Research Centers, Pharma & Biotech Companies, Hospitals & Clinics

Renub Research offers customizable reports with detailed company profiling, revenue forecasts, and strategic insights to empower stakeholders across the value chain.

❓ Frequently Asked Questions (FAQs) – United States Next Generation Sequencing Market

1. What is the current market size of the United States NGS market?

As of 2023, the U.S. Next Generation Sequencing market is valued at US$ 3.16 billion.

2. What is the forecasted market size by 2032?

The market is projected to reach US$ 13.75 billion by 2032, growing at a CAGR of 17.75%.

3. What factors are driving this market growth?

• Technological advancements in sequencing platforms
• Rising demand for personalized and precision medicine
• Increased applications in oncology, prenatal diagnostics, and infectious disease surveillance
• Government funding and R&D investment in genomics

4. Which technologies are commonly used in NGS?

Popular technologies include:

• Sequencing by Synthesis (SBS)
• Ion Semiconductor Sequencing
• Nanopore Sequencing
• Single-Molecule Real-Time (SMRT) Sequencing

5. Which companies are leading the U.S. NGS market?

Key players include:

• Illumina
• Thermo Fisher Scientific
• QIAGEN
• Agilent Technologies
• Pacific Biosciences
• Roche

6. What are the major applications of NGS in healthcare?

• Cancer diagnostics and tumor profiling
• Non-invasive prenatal testing (NIPT)
• Rare genetic disorder identification
• Infectious disease surveillance

7. What challenges does the NGS market face in the U.S.?

• High initial investment and operational costs
• Inconsistent reimbursement policies
• Data interpretation, storage, and privacy concerns

8. How is NGS contributing to drug discovery?

NGS aids in:

• Identifying novel genetic targets
• Stratifying patient populations
• Enabling personalized drug development
• Accelerating biomarker validation and clinical trials

9. What role does the U.S. government play in supporting NGS?

Through initiatives like the American Rescue Plan and CDC funding, the U.S. government supports genomic surveillance and innovation, helping scale up NGS infrastructure and research capabilities.

10. Can the report be customized for specific needs?

Yes, Renub Research offers up to 20% customization on request, including additional country or segment analysis, strategic market entry plans, and more company profiles.